News in Numbers

300,000

Bladder cancer diagnoses are set to climb to over 300,000 in by 2033 in the eight major markets, with men and over-60s most at risk, according to a new report by GlobalData.

$800m

GSK is planning to invest up to $800m in the US to double the size and capacity of its site in Marietta, Pennsylvania.

30%

Pfizer has reported a 30% year over year increase in revenues in Q3 2024 compared to last year largely due to sales from the company’s Covid-19 drugs Paxlovid and Comirnaty.

$280m

Eisai has lowered its revenue forecast for Q2 2024 for its Alzheimer’s drug Leqembi (lecanemab) to $280m from $370m, primarily citing delays in revenue in the US.

45%

Canadian biotech Aurinia Pharmaceuticals has announced it will be axing its workforce by 45% in a major restructuring plan aimed at streamlining operations.

Go to article: Home | Pharma's green shift with dry powder inhalersGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Alphial - CPHIGo to article: Syngene Company InsightGo to article: In DepthGo to article: Pharma's green shift: dry powder inhalers promise lower emissionsGo to article: Psoriasis biosimilars and pricing changes herald treatment paradigm disruptionsGo to article: What is the pharmacy of the future?Go to article: Obesity trial surge puts the focus back on decentralisationGo to article: A slow start for self-amplifying mRNA vaccinesGo to article: For pharma companies, the possibilities of green chemistry are hugeGo to article: Will the tide turn for the wave of pharma layoffs?Go to article: Investment and Development Agency of Latvia Company InsightGo to article: AlfatestLAB - CPHIGo to article: Sponsored SupplementsGo to article: RHEACELL Company InsightGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue